Hydrochloric Acid → Afuresertib Hydrochloride
反応式
[NH2:1][CH2:2][C@@H:3]([NH:12][C:13]([C:15]1[S:16][C:17]([Cl:27])=[C:18]([C:20]2[N:24]([CH3:25])[N:23]=[CH:22][C:21]=2[Cl:26])[CH:19]=1)=[O:14])[CH2:4][C:5]1[CH:10]=[CH:9][CH:8]=[C:7]([F:11])[CH:6]=1.Cl>O1CCOCC1>[ClH:26].[NH2:1][CH2:2][C@@H:3]([NH:12][C:13]([C:15]1[S:16][C:17]([Cl:27])=[C:18]([C:20]2[N:24]([CH3:25])[N:23]=[CH:22][C:21]=2[Cl:26])[CH:19]=1)=[O:14])[CH2:4][C:5]1[CH:10]=[CH:9][CH:8]=[C:7]([F:11])[CH:6]=1参加物
4
実験手順
The hydrochloride salt of N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide prepared generally as described in Example 96 of International Application No. PCT/US2008/053269, having an International Filing date of Feb. 7, 2008, and having International Publication Number WO/2008/098104 and an International Publication Date of Aug. 14, 2008, which generally states that the free base compound, N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, is treated with 4M HCl in dioxane and after 5 min, the solution is concentrated and dried under vacuum to afford N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride, yielded an amorphous solid as indicated by the Powder X-Ray Diffraction (PXRD) pattern depicted in FIG. 3.